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Abstract
The aim of this work was to evaluate the methylation profile of the p15 (CDKN2B) gene in Brazilian patients with leu-
kemia and to correlate the CDKN2B gene expression with the percentage of methylated CpG dinucleotides in its pro-
moter region. Thirty-one samples from six patients with acute lymphocytic leukemia (ALL), four with chronic myeloid
leukemia (CML), and 21 with acute myeloid leukemia (AML) were evaluated by MSP (Methylation-Specific PCR).
The CDKN2B gene was found to be methylated in four (67%) of the six ALL samples and in 16 (76%) of the 21 AML
samples, but in none of the four CML samples analyzed. We observed a correlation between the CDKN2B mRNA ex-
pression (RT-PCR) and the percentage of methylated CpG dinucleotides. Therefore, this study in Brazilian patients
confirms that the CDKN2B gene is methylated in the majority of leukemia patients.
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Introduction
DNA methylation is a covalent modification and re-
sults from the activity of a family of DNA methyltrans-
ferase (DNMT) enzymes which catalyze the transfer of a
methyl group (CH3) from S-adenosylmethionine (SAM) to
the cytosine residues at CpG dinucleotides (Strathdee and
Brown, 2002). The distribution of CpG dinucleotides in the
human genome is not uniform, but there are small stretches
(0.5 kb to several kb) of CpG-rich DNA regions termed
CpG islands (Galm et al., 2006). It has been estimated that
the human genome contains about 29,000 CpG islands
(Nephew and Huang, 2003). These CpG islands are usually
located in the vicinity of genes, are often found near the
promoters of widely expressed genes, and typically extend
into the first exon (Jones, 2003). In contrast to CpG dinu-
cleotides, which are dispersed throughout the genome, the
cytosines within CpG islands, especially those associated
with promoter regions, are normally unmethylated, allow-
ing the expression of a gene. The exception to this unme-
thylated state of CpG islands involves the imprinted genes
and X-chromosome inactivation, and this indicates the tight
association of promoter DNA methylation with transcrip-
tional silencing during normal mammalian development
(Galm et al., 2006).
The methylation pattern of normal cells is kept
through successive cellular divisions in adult tissues and
the heritage of this information is called epigenetic inheri-
tance (Laird, 2003). Therefore, epigenetics is the study of
modifications in gene expression that are not caused by al-
terations of DNA sequence (Verma and Srivastava, 2002;
Galm et al., 2006).
In tumorigenesis, the balance of the methylation state
of normal cells is lost, and some of the possible alterations
are: (I) transcriptional silencing of tumor suppressor genes
by CpG island promoter hypermethylation; and (II) histone
deacetylation and global genomic hypomethylation. Hypo-
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methylation contributes to carcinogenesis and is responsi-
ble for the chromosomal instability, reactivation of
transposable elements, and loss of imprinting (Esteller and
Herman, 2002). Therefore, the profile of hypermethylation
promoters differs according to each cancer type, because
for each tumor type specific genes are methylated. In addi-
tion to that, the epigenetic inactivation may affect all mo-
lecular mechanisms involved in cell immortalization and
transformation. Last but not least, it seems that epigenetic
changes are among the several early steps in carcinogenesis
(Mukai and Sekiguchi, 2002).
According to the estimates of cancer incidence for
2008 by INCA (Instituto Nacional do Câncer – Brazilian
National Cancer Institute), leukemias will afflict 5220 men
and 4320 women. Hematologic neoplasias can jeopardize
the lymphoid or myeloid lineages. Lymphoid neoplasias
start from lymphoid lineage cells in different stages of mat-
uration. Myeloid neoplasias result from a pluripotential
progenitor cell mutation which maintain the capacity, albeit
in an imperfect manner, of differentiation and maturation
for each one of the myeloid lineages (Zago et al., 2001).
Most acute leukemias appear to be the consequence of the
collaboration between one class of mutations or gene rear-
rangements that confer a proliferative and/or survival ad-
vantage to hematopoietic progenitors and a second class of
mutations that serve primarily to impair hematopoietic dif-
ferentiation and subsequent apoptosis of cells (Kelly and
Gilliland, 2002).
In hematological neoplasms, hypermethylation
genes were identified in multiple fundamental pathways
related to cancer, including cell cycle control (p15, p16,
Rb1, p27, p73), DNA repair (O6MGMT), apoptosis inhibi-
tion (DAPK), tumoral metastasis (E-cadherin), and
growth factors (ER, EphA3) (French et al., 2002). One of
the most frequent methylated genes in leukemia, mainly in
ALM, is CDKN2B (Herman et al., 1996; Issa et al., 1997;
Wong et al., 2000; Toyota et al., 2001; Claus and Lubbert,
2003).
In this work, we determined the methylation profile
of the CDKN2B gene in samples from Brazilian patients
with acute myeloid leukemia (AML), acute lymphocytic
leukemia (ALL), and chronic myeloid leukemia (CML).
We also evaluated the CDKN2B mRNA expression and the
percentage of methylated CpG dinucleotides by sequencing
of sodium bisulfite-treated DNA.
Material and Methods
Samples
Genomic DNA was extracted from bone marrow cells
of six ALL patients, four CML patients, 21 AML patients
and one sample of normal bone marrow, using a Super Quik
Gene Kit (AGTC). The AML samples were subdivided
based on French-American-British (FAB) into: M0 (1), M1
(2), M2 (10), M4 (2), M5 (4) and M6 (2). All patients
signed a consent form approved by the Ethics Committee of
the Institution.
Bisulfite DNA modification
Bisulfite DNA modification was accomplished in
agreement with the technique described in Current Proto-
cols In Human Genetics (Dracopoli et al., 1994). DNA
(2 μg) was denatured with NaOH (2 M) for 10 min at 37 °C.
Ten millimoles of hydroquinone and 3 M of sodium
bisulfite at pH 5, both freshly prepared, were added and
mixed, and then samples were incubated at 50 °C for 16 h.
The modified DNA was purified using a Wizard DNA
clean-up purification kit (Promega) according to the manu-
facturer’s instructions and eluted into water. Modification
was completed by treatment with NaOH 3 M for 5 min at
room temperature, followed by ethanol precipitation. The
DNA was resuspended in water and used immediately or
stored at -80 °C.
Methylation-Specific PCR (MSP)
A modified DNA was used for two MSP reactions,
both for the CDKN2B gene: one reaction specific for meth-
ylated DNA and other specific for unmethylated DNA. The
primer sequences used were: CDKN2B-F(M) 5’-CGTTCG
TATTTTGCGGTT-3’; CDKN2B-R(M) 5’-CGTACAATA
ACCGAACGACCGA-3’; CDKN2B-F(U) 5’ -TGTGATG
TGTTTGTATTTTGTGGTT-3’; and CDKN2B-R(U) 5’-
CCATACAATAACCAAACAACCAA-3’ (Herman et al.,
1996). For all reactions the amplification conditions were:
bisulfite-modified DNA; 10X PCR buffer (Invitrogen);
50 mM MgCl2; 1.25 mM dNTP, and 300 ng/μL of each
primer. Reactions were hot-started at 95 °C for 5 min be-
fore addition of 1.25 units of Taq polymerase (Invitrogen),
followed by 35 cycles (30 s at 95 °C, 30 s at 61 °C for
primer methylated or 60 °C for primer unmethylated, 30 s
at 72 °C), and a final extension step of 4 min at 72 °C. Each
PCR product was analyzed using 3% agarose gel, stained
with ethidium bromide and directly visualized under UV il-
lumination.
Sequencing of sodium bisulfite-treated DNA
Bisulfite-treated DNA was amplified by a nested-
PCR protocol, using the following primers: CDKN2B-F1
5’-GGTTGAAGGAATAGAAATTT-3’ and CDKN2B-R1
5’-ACACTCTTCCCTTCTTTCCC-3’ for the first reac-
tion; and CDKN2B-F2 5’-TTAGTTTTGGTTTTATTGG
A-3’ and CDKN2B-R2 5’-TCTCTCCTTCCTAAAAAAC
C-3’ for the second reaction. PCR was performed in a solu-
tion containing 10 X buffer (Biotools); 1.25 mM dNTP;
2.5 μM of each primer, and 2U of Taq DNA polymerase
(Biotools). The PCR conditions were: 94 °C for 5 min and
55 °C for 2 min, followed by 35 cycles (72 °C for 1 min,
94 °C for 1 min, and 55 °C for 1 min) and 72 °C for 10 min
for the first reaction. For the nested reaction the conditions
were similar, only the annealing temperature being chan-
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ged to 51 °C. The amplified products were sequenced di-
rectly in a MegaBace 1000 sequencer.
RNA isolation and reverse transcriptase PCR
(RT-PCR)
Total RNA was isolated using TRIZOL (Invitrogen)
and the cDNA was synthesized with the use of a High Ca-
pacity kit (Applied Biosystems). Amplification of
CDKN2B mRNA was performed with specific primers:
CDKN2B-RTF 5’-AACGGAGTCAACCGTTTCGG-3’
and CDKN2B-RTR 5’-TGTGCGCAGGTACCCTGCA
A-3’ (Hoshino et al., 2002). The PCR conditions were as
follows: 10 X buffer (Biotools); 1.25 mM dNTP; 20 pmol
of each primer, and 2 U of Taq DNA polymerase (Bio-
tools). PCR was initiated with one cycle at 95 °C for 1 min,
followed by 30 cycles at 95 °C for 1 min, 55 °C for 1 min,
and 72 °C for 1 min. The internal control was the glyceral-
dehyde 3-phosphate dehydrogenase (GAPDH) gene. The
amplified products were analyzed on 1.5% agarose gel,
stained with ethidium bromide and directly visualized un-
der UV illumination.
Results
Methylation analysis
Different methylation patterns of the CDKN2B gene
were detected among leukemia types analyzed by MSP.
The gene was methylated in four (67%) of the six ALL
samples and in 16 (76%) of the 21 AML samples, but in
none of the four CML samples analyzed. Regarding AML
subtypes, the frequency distribution of CDKN2B gene
methylation was: M0 1/1, M1 2/2, M2 9/10, M4 0/2, M5
3/4, and M6 1/2. In 12 AML samples, amplification was
achieved with both primers, specific for methylated DNA
and for unmethylated DNA, and therefore these samples
were classified as hemimethylated (Figure 1). For fre-
quency estimates, these hemimethylated samples were con-
sidered as methylated.
Expression analysis
The expression of CDKN2B mRNA was evaluated in
19 samples with available RNA (six methylated, five un-
methylated, and eight hemimethylated) and in one normal
bone marrow sample. In the methylated samples, no
CDKN2B mRNA expression was detected (Figure 2A). On
the other hand, CDKN2B expression was detected in the
unmethylated and in some hemimethylated samples (Fig-
ures 2B and C). However, the level of expression was
higher in the unmethylated than in the hemimethylated
samples. The highest level of CDKN2B gene expression
was detected in the normal bone marrow sample.
Sequencing analysis
The region analyzed (498 bp) after bisulfite treatment
of the DNA is located approximately -234 to +264 bp from
the transcription start site, comprising two CpG islands ac-
cording to the MethPrimer program (Li and Dahiya, 2002).
However, the CpG dinucleotides analyzed by sequencing
contained only the region located -15 to +208 bp (223 bp)
from the transcription start site that shows 26 CpG di-
nucleotides. The sequence amplified by MSP (147 bp),
which shows 19 CpG dinucleotides, is within the se-
quenced region (Figure 3).
Thirteen out of the 31 samples analyzed by MSP were
sequenced (one normal bone marrow, four methylated, four
hemimethylated and four unmethylated). The methylation
percentage for each sample was calculated as the number of
methylated CpG dinucleotides in the total number of ana-
lyzed CpGs (Figure 4). The normal sample did not show
any methylated CpG (data not shown). Seven out of eight
samples, which were amplified with the primer set specific
for the methylated DNA, presented a methylated CpG fre-
quency of 46% to 100%. The exception was sample XIX
(Figure 4), considered to be hemimethylated by MSP,
which showed only 26% of methylated CpG dinucleotides.
In the unmethylated samples, the percentage of methylated
CpGs ranged from 15% to 46%.
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Figure 1 - MSP of CDKN2B. Primer sets used for amplification are designated as methylated (M) or unmethylated (U). The leukemia samples are repre-
sented in Roman numbers. NBM = normal bone marrow. (A) Samples amplified with methylated primer set. (B) Samples amplified with methylated and
unmethylated primer sets. (C) Samples amplified with unmethylated primer set.
Discussion
The CDKN2B gene encodes a 15-kDa protein that is a
cyclin-dependent kinase inhibitor. The role of CDKN2B as
a tumor suppressor in acute myelogenous leukemia (AML)
was established in several previous studies (Herman et al.,
1996; Issa et al., 1997; Wong et al., 2000; Toyota et al.,
2001; Claus and Lubbert, 2003). Hypermethylation of
CDKN2B CpG islands has been shown to occur in up to
80% of human AML, and this epigenetic state is associated
with reduced expression (Markus et al., 2007).
In this study, analysis results of the methylated state
of the CDKN2B gene, performed by MSP, were confirmed
by direct sequencing and expression analysis. Our MSP re-
sults showed that CDKN2B was methylated in 76% of the
AML samples. These results are in agreement with previ-
ous studies that found the CDKN2B gene to be methylated
in more than 50% of the cases (Herman et al., 1996; Issa et
al., 1997; Toyota et al., 2001; Claus and Lubbert, 2003).
Among patients with AML, Wong et al. (2000) re-
ported CDKN2B methylation frequencies to be higher in
subtypes M2, M3 or M4 than in M1, M5, M6 or M7. In nine
of our 10 subtype M2 samples, the gene was methylated;
for the other subtypes, the number of samples was too small
to allow a correlation analysis.
In ALL, previous studies indicated different methyl-
ation frequencies for the CDKN2B gene, depending on the
methodology used (Issa et al., 1997; Melki et al., 1999;
Garcia-Manero et al., 2002; Melki and Clark, 2002; Chim
et al., 2003). We found a higher frequency (67%) than that
(40%) described by Chim and colleagues (2003), using the
same methodology (MSP). This might be due to our smaller
sample size (six samples) compared to theirs (25 samples).
Even with a small number of LMC samples (four), our data
showed the unmethylated state of the CDKN2B gene,
which is in agreement with previous reports (Issa et al.,
1997; Toyota et al., 2001).
A sample of genomic DNA usually consists of a large
pool of molecules that may display methylation heteroge-
neity. This heterogeneity can be due to the fact that two al-
leles of any given genomic locus in a cell may differ in their
methylation patterns, and that the DNA sample was derived
from multiple cells with potentially different methylation
patterns (Siegmund and Laird, 2002). This could explain
the simultaneous amplification by MSP using primer sets
for both methylated and unmethylated DNA. This methyl-
ation heterogeneity of samples can also be difficult to ana-
lyze by direct sequencing of sodium bisulfite-treated DNA,
once it does not allow the methylation state of individual al-
leles to be determined. Hence, in some chromatograms the
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Figure 2 - CDKN2B mRNA expression evaluated by RT-PCR.
NBM = normal bone marrow. The samples are represented in roman num-
bers. (A) methylated samples (B) hemimethylated samples. (C)
unmethylated samples. (D) Comparative RT-PCR. GAPDH was used to
control the integrity of the RNA samples.
Figure 3 - CDKN2B gene sequence amplified by nested-PCR. The sequence analyzed by direct sequencing is highlighted in gray. The region amplified
by MSP is underlined. Intron sequences, in short letters, exon sequences, in capital letters, and CpG dinucleotides in boldface. RefSeq accession
NM_004936.
TCpG sequence was observed instead of TpG or CpG. We
expected to find TpG in the case of an unmethylated di-
nucleotide and CpG in the case of a methylated dinucleo-
tide. The term hemimethylated was also used to designate
those CpG nucleotides for which the methylation state
could not be defined by sequencing, as it occurred in CpG
04, 06 and 10 (Figure 5C).
In general, the amount of methylated CpG sites
within a locus, as well as the number of methylated loci, in-
crease in more advanced stages of cancer (Nephew and
Huang, 2003). The consequence of this dynamic epigenetic
gene silencing is that the degree of loss of protein produc-
tion is not uniform throughout the tumor-cell population,
unlike the one that is produced by the genetic changes
(Jones and Baylin, 2002). We analyzed the expression of
CDKN2B mRNA, which in general agreed both with the
MSP results and with the percentage of methylated CpG
dinucleotides, as determined by direct PCR sequencing. In
the methylated samples that showed more than 80% of
methylated CpG dinucleotides, no CDKN2B mRNA ex-
pression was observed by RT-PCR (Figures 2A and 4). In
the unmethylated samples, a relationship between the ex-
pression level and the percentage of methylated CpG was
observed, as in sample X (46% methylated CpG) and sam-
ples VIII and IX (15% and 17% methylated CpG, respec-
tively) (Figures 2C and 4). The CDKN2B gene expression
was very low when the gene was found to be hemimethyl-
ated by MSP (Figure 2B). CDKN2B mRNA expression dif-
fered between the normal bone marrow and the
unmethylated samples (Figure 2C). These unmethylated
samples showed a low percentage of methylated CpG,
which seems to correlate with the levels of mRNA tran-
scription.
The percentage of methylated CpGs was similar
(46%) in samples X and I (unmethylated and methylated,
respectively). However, their level of gene expression and
the number of hemimethylated CpGs (Figures 2D and 4)
were different. There were 10 hemimethylated CpGs in
sample I, while in sample X only 2 hemimethylated CpGs
were identified. Hence, the methylation density of the re-
gion analyzed was higher in sample I than in sample X, and
this might have caused the apparent difference in CDKN2B
gene expression observed between these samples.
Another difference between the samples was the state
of the methylated CpG 3 dinucleotide at the transcription
factor Sp1 site. Sp1 is associated with the transcription of
the CDKN2B gene and is a regulator of cell cycle progres-
sion (Pagliuca et al., 2000). Many factors are known to bind
CpG-containing sequences, and some of them fail to bind
when the CpG is methylated, therefore inhibiting transcrip-
tion (Bird, 2002). CpG 3 and CpG 25 are part of two Sp1
sites (Figure 4), and in seven of the eight sequenced sam-
ples which were amplified by the specific primer set for
methylated DNA at least one of these dinucleotide CpGs
was methylated (Figure 4).
Methylation of specific targets may explain the obser-
vation that different hematopoietic malignancies harbor
distinct methylation signatures (Rush and Plass, 2002). The
cell type-specific pattern of hypermethylation suggests that
the methylation of certain CpG islands may be used as dis-
ease marker and is also useful in the detection of minimal
residual disease after chemotherapy. This pattern may
therefore influence any adjuvant treatments (Melki and
Clark, 2002) or be used as a marker for disease progression
(Laird, 2003). Agrawal et al. (2007) showed increased
CDKN2B methylation levels in the bone marrow of patients
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Figure 4 - Scheme of direct bisulfite sequencing of region containing 26
CpG dinucleotides. Each circle represents a CpG dinucleotide. Spacing
between circles is relative. Open circle, unmethylated; black circle, meth-
ylated; partly open circle, hemimethylated. M, methylated; U, unmethyl-
ated and H, hemimethylated. The numbers at the top indicate the samples:
VIII, IX and X are unmethylated; XIII, XIV, XVIII and XIX, hemi-
methylated; I, II, III and IV, methylated. The numbers to the left indicate
the CpG dinucleotides, and those below, the percentage of methylation in
each sample. The CpG dinucleotides amplified by MSP are shown on the
right.
with acute leukemias in clinical remission and, according to
these authors, the presence of aberrant DNA methylation in
remission is a powerful indicator of a high risk of leukemia
relapse.
In this first report on the methylation status of the
CDKN2B gene in Brazilian leukemia patients, CDKN2B
was found to be methylated, in agreement with data ob-
tained in similar analyses performed in leukemia patients of
other countries.
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